Literature DB >> 29669022

DNA-mediated dimerization on a compact sequence signature controls enhancer engagement and regulation by FOXA1.

Xuecong Wang1,2,3, Yogesh Srivastava1,2,3, Aleksander Jankowski4,5,6, Vikas Malik1,2,3, Yuanjie Wei1,2,3, Ricardo Ch Del Rosario7, Vlad Cojocaru8,9, Shyam Prabhakar4, Ralf Jauch1,2,10.   

Abstract

FOXA1 is a transcription factor capable to bind silenced chromatin to direct context-dependent cell fate conversion. Here, we demonstrate that a compact palindromic DNA element (termed 'DIV' for its diverging half-sites) induces the homodimerization of FOXA1 with strongly positive cooperativity. Alternative structural models are consistent with either an indirect DNA-mediated cooperativity or a direct protein-protein interaction. The cooperative homodimer formation is strictly constrained by precise half-site spacing. Re-analysis of chromatin immunoprecipitation sequencing data indicates that the DIV is effectively targeted by FOXA1 in the context of chromatin. Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29669022      PMCID: PMC6009666          DOI: 10.1093/nar/gky259

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  78 in total

1.  Gene expression profiling of breast cell lines identifies potential new basal markers.

Authors:  E Charafe-Jauffret; C Ginestier; F Monville; P Finetti; J Adélaïde; N Cervera; S Fekairi; L Xerri; J Jacquemier; D Birnbaum; F Bertucci
Journal:  Oncogene       Date:  2006-04-06       Impact factor: 9.867

2.  Genome-wide analysis of estrogen receptor binding sites.

Authors:  Jason S Carroll; Clifford A Meyer; Jun Song; Wei Li; Timothy R Geistlinger; Jérôme Eeckhoute; Alexander S Brodsky; Erika Krasnickas Keeton; Kirsten C Fertuck; Giles F Hall; Qianben Wang; Stefan Bekiranov; Victor Sementchenko; Edward A Fox; Pamela A Silver; Thomas R Gingeras; X Shirley Liu; Myles Brown
Journal:  Nat Genet       Date:  2006-10-01       Impact factor: 38.330

3.  FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.

Authors:  Mathieu Lupien; Jérôme Eeckhoute; Clifford A Meyer; Qianben Wang; Yong Zhang; Wei Li; Jason S Carroll; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2008-03-21       Impact factor: 41.582

4.  Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes.

Authors:  Vladimir Vacic; Laurie J Ozelius; Lorraine N Clark; Anat Bar-Shira; Mali Gana-Weisz; Tanya Gurevich; Alexander Gusev; Merav Kedmi; Eimear E Kenny; Xinmin Liu; Helen Mejia-Santana; Anat Mirelman; Deborah Raymond; Rachel Saunders-Pullman; Robert J Desnick; Gil Atzmon; Edward R Burns; Harry Ostrer; Hakon Hakonarson; Aviv Bergman; Nir Barzilai; Ariel Darvasi; Inga Peter; Saurav Guha; Todd Lencz; Nir Giladi; Karen Marder; Itsik Pe'er; Susan B Bressman; Avi Orr-Urtreger
Journal:  Hum Mol Genet       Date:  2014-05-19       Impact factor: 6.150

5.  Fast gapped-read alignment with Bowtie 2.

Authors:  Ben Langmead; Steven L Salzberg
Journal:  Nat Methods       Date:  2012-03-04       Impact factor: 28.547

6.  Theoretical aspects of DNA-protein interactions: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice.

Authors:  J D McGhee; P H von Hippel
Journal:  J Mol Biol       Date:  1974-06-25       Impact factor: 5.469

Review 7.  Unraveling the role of FoxOs in bone--insights from mouse models.

Authors:  Maria Almeida
Journal:  Bone       Date:  2011-06-01       Impact factor: 4.398

8.  Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

Authors:  Chad J Creighton; Suleiman Massarweh; Shixia Huang; Anna Tsimelzon; Susan G Hilsenbeck; C Kent Osborne; Jiang Shou; Luca Malorni; Rachel Schiff
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

9.  Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease.

Authors:  Sang-Min Oh; Mi-Yoon Chang; Jae-Jin Song; Yong-Hee Rhee; Eun-Hye Joe; Hyun-Seob Lee; Sang-Hoon Yi; Sang-Hun Lee
Journal:  EMBO Mol Med       Date:  2016-02-01       Impact factor: 12.137

10.  Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer.

Authors:  Benjamin A Katchman; I Tolgay Ocal; Heather E Cunliffe; Yu-Hui Chang; Galen Hostetter; Aprill Watanabe; Janine LoBello; Douglas F Lake
Journal:  Breast Cancer Res       Date:  2013-03-28       Impact factor: 6.466

View more
  7 in total

1.  FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.

Authors:  Amaia Arruabarrena-Aristorena; Jesper L V Maag; Srushti Kittane; Yanyan Cai; Wouter R Karthaus; Erik Ladewig; Jane Park; Srinivasaraghavan Kannan; Lorenzo Ferrando; Emiliano Cocco; Sik Y Ho; Daisylyn S Tan; Mirna Sallaku; Fan Wu; Barbara Acevedo; Pier Selenica; Dara S Ross; Matthew Witkin; Charles L Sawyers; Jorge S Reis-Filho; Chandra S Verma; Ralf Jauch; Richard Koche; José Baselga; Pedram Razavi; Eneda Toska; Maurizio Scaltriti
Journal:  Cancer Cell       Date:  2020-09-03       Impact factor: 31.743

2.  Directed Evolution of an Enhanced POU Reprogramming Factor for Cell Fate Engineering.

Authors:  Daisylyn Senna Tan; Yanpu Chen; Ya Gao; Anastasia Bednarz; Yuanjie Wei; Vikas Malik; Derek Hoi-Hang Ho; Mingxi Weng; Sik Yin Ho; Yogesh Srivastava; Sergiy Velychko; Xiaoxiao Yang; Ligang Fan; Johnny Kim; Johannes Graumann; Gary D Stormo; Thomas Braun; Jian Yan; Hans R Schöler; Ralf Jauch
Journal:  Mol Biol Evol       Date:  2021-06-25       Impact factor: 16.240

3.  FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.

Authors:  Elizabeth J Adams; Wouter R Karthaus; Elizabeth Hoover; Deli Liu; Antoine Gruet; Zeda Zhang; Hyunwoo Cho; Rose DiLoreto; Sagar Chhangawala; Yang Liu; Philip A Watson; Elai Davicioni; Andrea Sboner; Christopher E Barbieri; Rohit Bose; Christina S Leslie; Charles L Sawyers
Journal:  Nature       Date:  2019-06-26       Impact factor: 49.962

Review 4.  Toward a mechanistic understanding of DNA binding by forkhead transcription factors and its perturbation by pathogenic mutations.

Authors:  Shuyan Dai; Linzhi Qu; Jun Li; Yongheng Chen
Journal:  Nucleic Acids Res       Date:  2021-10-11       Impact factor: 16.971

5.  The landscape of GWAS validation; systematic review identifying 309 validated non-coding variants across 130 human diseases.

Authors:  Ammar J Alsheikh; Sabrina Wollenhaupt; Emily A King; Jonas Reeb; Sujana Ghosh; Lindsay R Stolzenburg; Saleh Tamim; Jozef Lazar; J Wade Davis; Howard J Jacob
Journal:  BMC Med Genomics       Date:  2022-04-01       Impact factor: 3.063

6.  FOXL2 and FOXA1 cooperatively assemble on the TP53 promoter in alternative dimer configurations.

Authors:  Yuri Choi; Yongyang Luo; Seunghwa Lee; Hanyong Jin; Hye-Jin Yoon; Yoonsoo Hahn; Jeehyeon Bae; Hyung Ho Lee
Journal:  Nucleic Acids Res       Date:  2022-08-26       Impact factor: 19.160

Review 7.  The FOXO's Advantages of Being a Family: Considerations on Function and Evolution.

Authors:  Michel Schmitt-Ney
Journal:  Cells       Date:  2020-03-24       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.